Search

Your search keyword '"Jenkins V"' showing total 24 results
Start Over Author "Jenkins V" Publisher springer science and business media llc
24 results on '"Jenkins V"'

2. Patients’ experiences of a suppoRted self-manAGeMent pAThway In breast Cancer (PRAGMATIC): quality of life and service use results

Author

Jenkins, V, primary, Matthews, L, additional, Solis-Trapala, I, additional, Gage, H, additional, May, S, additional, Williams, P, additional, Bloomfield, D, additional, Zammit, C, additional, Elwell-Sutton, D, additional, Betal, D, additional, Finlay, J, additional, Nicholson, K, additional, Kothari, M, additional, Santos, R, additional, Stewart, E, additional, Bell, S, additional, McKinna, F, additional, and Teoh, M, additional

Published
2023
Full Text
View/download PDF

13. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer

Author

Jenkins, V, primary, Shilling, V, additional, Deutsch, G, additional, Bloomfield, D, additional, Morris, R, additional, Allan, S, additional, Bishop, H, additional, Hodson, N, additional, Mitra, S, additional, Sadler, G, additional, Shah, E, additional, Stein, R, additional, Whitehead, S, additional, and Winstanley, J, additional

Published
2006
Full Text
View/download PDF

24. Do drugs offering only PFS maintain quality of life sufficiently from a patient's perspective? Results from AVALPROFS (Assessing the 'VALue' to patients of PROgression Free Survival) study

Author

Susan Catt, J. Dickson, Valerie Shilling, Richard Simcock, Valerie Jenkins, L. Matthews, Vern Farewell, Shirley May, Lesley Fallowfield, Jenkins, V [0000-0001-8939-0081], and Apollo - University of Cambridge Repository

Subjects
Quality of life, Adult, Male, medicine.medical_specialty, Side effect, Cancer therapy, Disease, Disease-Free Survival, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Neoplasms, Surveys and Questionnaires, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, 030212 general & internal medicine, Progression-free survival, Neoplasm Metastasis, Side effects, Aged, Aged, 80 and over, business.industry, Cancer, Drugs, Investigational, Middle Aged, medicine.disease, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, Toxicity, Disease Progression, Patients’ views, Original Article, Female, Perception, Risk of death, Immunotherapy, business, Attitude to Health
Abstract

Purpose Trials of novel drugs used in advanced disease often show only progression-free survival or modest overall survival benefits. Hypothetical studies suggest that stabilisation of metastatic disease and/or symptom burden are worth treatment-related side effects. We examined this premise contemporaneously using qualitative and quantitative methods. Methods Patients with metastatic cancers expected to live > 6 months and prescribed drugs aimed at cancer control were interviewed: at baseline, at 6 weeks, at progression, and if treatment was stopped for toxicity. They also completed Functional Assessment of Cancer Therapy (FACT-G) plus Anti-Angiogenesis (AA) subscale questionnaires at baseline then monthly for 6 months. Results Ninety out of 120 (75%) eligible patients participated: 41 (45%) remained on study for 6 months, 36 progressed or died, 4 had treatment breaks, and 9 withdrew due to toxicity. By 6 weeks, 66/69 (96%) patients were experiencing side effects which impacted their activities. Low QoL scores at baseline did not predict a higher risk of death or dropout. At 6-week interviews, as the side effect severity increased, patients were significantly less inclined to view the benefit of cancer control as worthwhile (X2 = 50.7, P

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results